Conditions: Migraine Disorders
Keywords: Migraine headache
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1959
Healthy volunteers: no

Brief summary:
This record describes pooled data for three extension studies: MK-0462-022 (NCT00897949); MK-0462-025 (NCT00899379); and MK-0462-029 (NCT00897104). These studies examined the long-term safety and efficacy of rizatriptan used for the treatment of acute migraine and migraine recurrence.

Detailed description:

Arms:
arm 1: Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s) arm 2: Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s) arm 3: Standard care at onset of migraine attack

Interventions: intervention 1: Rizatriptan 5 mg intervention 2: Rizatriptan 10 mg intervention 3: Standard Care
Intervention descriptions: intervention 1: Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s) intervention 2: Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s) intervention 3: Active standard care

Protocol document: